Maternal blood concentration of tadalafil in pregnancy: Comparison of pregnant and non-pregnant women

Taiwan J Obstet Gynecol. 2022 Mar;61(2):230-233. doi: 10.1016/j.tjog.2022.02.009.

Abstract

Objective: In this study, the drug kinetics of tadalafil were compared between pregnant and non-pregnant women to determine the ideal dosage to promote uterine blood flow.

Materials and methods: We recruited five pregnant and five non-pregnant women, all of which were administered tadalafil (20 mg/day). The blood concentration of tadalafil was measured 1, 2, 4, 6, 8, and 24 h after administration. We investigated the side effects within 4 days of tadalafil administration and compared the cumulative frequency between the two groups.

Results: The mean area under the concentration-time curve and maximum blood concentration of tadalafil were not different between the pregnant and non-pregnant groups. Time to maximum blood concentration was delayed by 1 min on average in the pregnant group compared with the non-pregnant group. The cumulative frequency of side effects was significantly lower in the pregnant group than in the non-pregnant group (P = 0.026). No side effects were observed in either group after the fifth day of the tadalafil administration.

Conclusion: Although there was no difference in maximum blood concentration between non-pregnant and pregnant women, the rate of side effects was lower in pregnant women than in non-pregnant women. Therefore, pregnant women may tolerate tadalafil better.

Keywords: Blood concentration; Fetal growth restriction; Pregnancy; Tadalafil; Uterine artery.

Publication types

  • Retracted Publication

MeSH terms

  • Female
  • Fetal Growth Retardation* / drug therapy
  • Humans
  • Placental Circulation
  • Pregnancy
  • Pregnant Women*
  • Tadalafil / adverse effects

Substances

  • Tadalafil